These findings reveal criticalmolecular and prognostic differences between LCC and RCC and highlight SMAD4 and SETD2 asimportant prognostic biomarkers, suggesting the potential value of location‐and mutation‐guided precision therapies in CRC. This evidence concerns the gene SMAD4 and leukoencephalopathy with calcifications and cysts.